bronchitis%20-%20chronic%20in%20acute%20exacerbation
BRONCHITIS - CHRONIC IN ACUTE EXACERBATION

Chronic bronchitis is an infection of the trachea and bronchi for at least 3 consecutive months for more than 2 consecutive years.
The patient experiences symptoms of increase in dyspnea, sputum volume and sputum purulence over baseline on most days.

Diagnosis is basically based on clinical presentation.

Prevention

Influenza Vaccine

  • The use of an annual influenza vaccine for all patients with chronic bronchitis is strongly recommended
    • Patients with chronic lung disease have a higher risk of complications from influenza infection
    • Annual influenza vaccination decreases the morbidity and mortality of influenza in the elderly by 50%
  • Please see Influenza disease management chart for further information

Pneumococcal Vaccine

  • It is recommended that pneumococcal vaccine be administered at least once to patients with chronic bronchitis
    • Consider repeating vaccine every 5-10 years in high-risk patients
  • Pneumococcal vaccine is safe and may reduce invasive pneumococcal infection in patients with COPD
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2019
Urogenital infections remain a major reason for women to visit their family physician and their subsequent referral to obstetrics and gynaecology or urology specialists. The association between abnormal vaginal microbiota and an increased risk of contracting sexually transmitted diseases (STDs), as well as an increased rate of preterm labour, indicates the need to better understand and manage urogenital health in women. Probiotics are “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”. As such, there is a sound rationale for using probiotics to maintain female vaginal and bladder health.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.